FDA Approvals, News & Updates
Previously approved for thyroid cancer and kidney cancer, the FDA has recently approved Lenvima as the first treatment for patients with liver cancer. Read More ›
The use of Opdivo with Yervoy is the first immunotherapy combination therapy approved by the FDA for patients with kidney cancer. Read More ›
On February 14, 2018, the FDA approved Erleada (apalutamide; from Janssen) for the treatment of patients with nonmetastatic, castration-resistant prostate cancer. Read More ›
The CDK4/CDK6 inhibitor Verzenio received a new indication, for use alone or in combination with an aromatase inhibitor, as initial therapy in women with HR-positive, HER2-negative advanced or metastatic breast cancer. Read More ›
